PAI-1 Inhibitor (MDI-2517) demonstrates good safety and tolerability profile, with Phase 2 proof-of-concept trial planned for 2026 in patients with metabolic and fibrotic disease Carmel Nanthakumar, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results